Ipsen Biopharm Ltd. is a subsidiary of Ipsen S.A., a global biopharmaceutical group. Ipsen S.A. is a French public company, founded in 1929 by Henri Beaufour, and is headquartered in Paris, France. The parent company, Ipsen S.A., is publicly traded on Euronext Paris (IPN) and has approximately 5,000 to 5,700 employees worldwide. As of December 2025, Ipsen S.A. reported a trailing 12-month revenue of $4.43 billion and a market capitalization of $15.1 billion as of May 2026. Ipsen Biopharm Ltd. specifically has its UK headquarters for development and manufacturing in Wrexham, UK, which is a neuroscience center of excellence, and also has commercial operations in London.
Ipsen focuses on the research, development, and commercialization of innovative medicines in three key therapeutic areas: oncology, rare diseases, and neuroscience. Their product portfolio includes drugs such as Somatuline® (lanreotide) for neuroendocrine tumors and acromegaly, Dysport® (abobotulinumtoxinA) for neurological conditions like spasticity and cervical dystonia, and Onivyde® (irinotecan liposome injection) for pancreatic cancer. The company also develops treatments for rare liver diseases and fibrodysplasia ossificans progressiva.
Ipsen Biopharm Ltd. primarily operates as an operating company, as indicated by its patent litigation posture. The company has been a defendant in two cases and a plaintiff in one, suggesting it actively defends its intellectual property while also asserting its rights when necessary. Its involvement as a defendant in cases brought by Unified Patents and CSPC Pharmaceutical Group Limited, alongside its plaintiff role in a suit against Conjuprio Biotherapeutics, Inc., points to a two-way litigation posture typical of a pharmaceutical company actively protecting its drug patents.
Notable cases include CSPC Pharmaceutical Group Limited et al. v. Ipsen Biopharm Ltd. and Unified Patents v. Ipsen Biopharm Ltd., both before the Patent Trial and Appeal Board (PTAB), where Ipsen Biopharm Ltd. was the defendant. Additionally, IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al. is a case where an Ipsen entity is acting as a plaintiff in the U.S. District Court for the District of New Jersey. These cases likely involve patents related to Ipsen's core therapeutic areas of oncology, rare diseases, or neuroscience, reflecting the company's commitment to its pharmaceutical product lines.Ipsen Biopharm Ltd. is a subsidiary of Ipsen S.A., a French global biopharmaceutical group founded in 1929 by Henri Beaufour. Ipsen S.A. is headquartered in Paris, France, and is publicly traded on Euronext Paris under the ticker IPN. The parent company employs approximately 5,000 to 5,700 people worldwide, reported a trailing 12-month revenue of $4.43 billion as of December 2025, and had a market capitalization of $15.1 billion as of May 2026. Ipsen Biopharm Ltd. operates a significant development and manufacturing facility in Wrexham, UK, specializing in neuroscience, and maintains commercial operations in London.
The company focuses on the research, development, and commercialization of innovative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Its product portfolio includes key treatments such as Somatuline® (lanreotide) for neuroendocrine tumors and acromegaly, Dysport® (abobotulinumtoxinA) for various neurological conditions including spasticity and cervical dystonia, and Onivyde® (irinotecan liposome injection) for pancreatic cancer. Ipsen also develops therapies for rare liver diseases and fibrodysplasia ossificans progressiva.
Ipsen Biopharm Ltd. exhibits a two-way patent litigation posture, acting as both a defendant and a plaintiff in tracked cases. With two instances as a defendant and one as a plaintiff, the company actively defends its intellectual property rights against challenges while also asserting its own patents. This posture is typical of an operating pharmaceutical company engaged in competitive drug development and commercialization.
Notable cases include CSPC Pharmaceutical Group Limited et al. v. Ipsen Biopharm Ltd. and Unified Patents v. Ipsen Biopharm Ltd., both heard before the Patent Trial and Appeal Board (PTAB), where Ipsen Biopharm Ltd. was the defendant. Conversely, Ipsen Biopharm Ltd. is a plaintiff in IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al. in the U.S. District Court for the District of New Jersey. These cases underscore the company's engagement in protecting its pharmaceutical innovations, likely related to its specialized therapeutic areas.